Pediatric patients with relapsed or refractory disease represent a population with a desperate medical need. The aim of the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) program is to translate next generation molecular diagnostics into a biomarker driven treatment strategy. | INFORM2 NivEnt The first trial of the INFORM2 biomarker driven phase I II trial series The combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
